Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

1.485 -0.055 (-3.57%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
From Editas Medicine, Inc.
Via GlobeNewswire
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector. 
Via InvestorPlace
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
From Editas Medicine, Inc.
Via GlobeNewswire
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that... 
Via Benzinga
Editas Medicine's Return On Capital Employed Insights
Via Benzinga
6 Analysts Have This to Say About Editas Medicine
Via Benzinga
Editas Medicine: Q1 Earnings Insights
Via Benzinga
7 Short-Squeeze Stocks Set for a May Rally
While targeting the best short-squeeze stocks to buy now can be incredibly treacherous, they may also yield robust returns. 
Via InvestorPlace
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
It's facing a few issues that are practically guaranteed to affect shareholder returns. 
Via The Motley Fool
Editas Medicine Reports Inducement Grant to New Chief Financial Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
Michelle Robertson to remain with Company until August 16, 2023 
From Editas Medicine, Inc.
Via GlobeNewswire
Preview: Editas Medicine's Earnings
Via Benzinga
2 Stocks Under $15 Per Share to Consider
Anyone can get in on the stock market at these prices. 
Via The Motley Fool
ONEOK, PacWest Bancorp And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
Company-sponsored webinar to be announced 
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces First Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
From Editas Medicine, Inc.
Via GlobeNewswire
Earnings Scheduled For May 5, 2023
Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly earnings at $0.32 per share on revenue of $5.08 billion. 
Via Benzinga
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
The 3 Most Promising Gene Editing Stocks to Buy in 2023
Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in. 
Via InvestorPlace
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end 
From Editas Medicine, Inc.
Via GlobeNewswire
Why Shares of Editas Medicine Rose Monday
The company is benefiting from positive news affecting other gene-editing stocks. 
Via The Motley Fool
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82. 
Via Benzinga
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks. 
Via InvestorPlace
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday. 
Via Benzinga
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
From Editas Medicine, Inc.
Via GlobeNewswire
Proceed With Caution When Considering These 5 Ultra-Popular Stocks
Four of these five stocks are losing money. 
Via The Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Neither stock is a good choice for those who can't handle a lot of risk. 
Via The Motley Fool
Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?
EDIT-301 had positive clinical results in treating sickle cell disease, but the potential payoff is still years in the future. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.